Clause Engineering: How MedTech Suppliers Can Protect Margin from Tariffs in the 2027 Contracting Cycle

Medical device tariffs have exposed a gap in how US healthcare contracts allocate risk. Buyers secured firm pricing. Many suppliers never secured the right to adjust it. As the 2027 contracting cycle approaches, the clauses in GPO and hospital agreements will decide how much of the next cost shock a supplier can recover.

In April 2025, Johnson & Johnson CFO Joe Wolk said existing medical device contracts left the company very limited scope to pass through an estimated $400 million tariff impact.¹ About two weeks later, Cardinal Health set out a different response to its projected $200 million to $300 million fiscal 2026 exposure: operational measures and customer price adjustments, particularly across its own-brand portfolio.² By January 2026, J&J’s MedTech tariff assumption for the year had reached approximately $500 million.³

The two companies differ in product mix, sourcing flexibility, channel structure, and negotiating leverage. Their disclosures cannot isolate the effect of contract language. They do raise the question every medtech commercial team should be asking: when costs change, how much room does your contract portfolio leave you?

That room depends on contract duration, adjustment rights, importer status, sourcing control, and customer relationships. Clause language turns those factors into rights a supplier can actually exercise. The 2027 cycle is the moment to redesign them, agreeing before the next disruption how cost changes will be evidenced, allocated, and reconciled.

Tariff policy moves faster than contract pricing

A contract signed in early 2025 has already crossed several tariff regimes.

The April 2025 IEEPA tariffs introduced widespread new duties. In February 2026, the Supreme Court ruled that IEEPA did not authorise the president to impose tariffs, opening the way for refunds. A temporary Section 122 surcharge followed. In July, Section 301 duties of 10% or 12.5% took effect across 60 trading partners, with significant exemptions and differentiated treatment.^{4, 6}

For commercial teams fixing prices for 12 or 24 months, the implication is clear. The policy assumptions behind a bid can change several times before the agreement expires.

Sector-specific measures add another layer. The pharmaceutical Section 232 framework pairs a headline 100% rate on covered patented products with lower country rates, product exceptions, and preferential treatment tied to approved onshoring plans and qualifying pricing agreements.⁷

MedTech now has its own example of investment commitments linked to tariff relief. On October 6, 2026, BD announced a US government agreement supporting $19 billion of investment over several years, including $3 billion for manufacturing expansion. The agreement provides relief from future Section 232 tariffs on covered products and inputs, conditional on the eventual measures and on BD meeting agreed milestones. BD said final rates, scope, and timing remain undetermined.²¹

This does not establish an industry-wide exemption model. It does confirm that tariff exposure will increasingly vary by supplier, product, and manufacturing footprint.

A fixed price stays fixed even when the policy behind its cost assumptions changes. Without an agreed adjustment mechanism, the supplier may have little contractual room to respond.